Maria D'Amico

Medicine & Life Sciences

1. Oxaliplatin 100%
2. Colonic Neoplasms 76%
3. eculizumab 42%
4. Coronavirus 35%
5. Stem Cell Factor 34%
6. End Stage Liver Disease 33%
7. Survival 31%
8. Mortality 30%
9. Intensive Care Units 30%
10. Microbial Drug Resistance 28%
11. Decompression 28%
12. Cardiology 27%
13. Hematopoietic Stem Cells 27%
14. Therapeutics 27%
15. Proteinuria 27%
16. Stents 27%
17. Immunoglobulin A 26%
18. Confidence Intervals 26%
19. Disease-Free Survival 25%
20. Critical Care 24%
21. Transjugular Intrahepatic Portasystemic Shunt 24%
22. Rheumatoid Arthritis 23%
23. Sepsis 22%
24. Recurrence 20%
25. Neoplasms 18%
26. Anti-Bacterial Agents 18%
27. Pediatrics 18%
28. Transplants 17%
29. Antirheumatic Agents 16%
30. Drug Therapy 16%
31. Infections 15%
32. Incidence 13%
33. Odds Ratio 13%
34. Surgical Portasystemic Shunt 12%
35. Comorbidity 11%
36. Methicillin Resistance 11%
37. Calibration 11%
38. Hematopoietic Stem Cell Transplantation 10%
39. Pneumonia 9%
40. Statistics 7%
41. Vancomycin Resistance 6%
42. C-Reactive Protein 6%
43. Janus Kinase Inhibitors 6%
44. Fibrosis 6%
45. Risk Reduction Behavior 6%
46. Cefepime 6%
47. Complement C5 6%
48. Antimicrobial Stewardship 6%
49. Tazobactam Drug Combination Piperacillin 6%
50. Meropenem 5%